Geordan G. Pursglove - 03 Jul 2025 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role: CEO and Chairman of the Board, Director
Signature: /s/ Geordan Pursglove
Issuer symbol: LIXT
Transactions as of: 03 Jul 2025
Net transactions value: $0
Form type: 4
Filing time: 09 Jul 2025, 18:37:33 UTC
Previous filing: 18 Jun 2025
Next filing: 18 Aug 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Pursglove Geordan Garrett	CEO and Chairman of the Board, Director	680 E. COLORADO BLVD., SUITE 180, PASADENA	/s/ Geordan Pursglove	08 Jul 2025	0002073519

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LIXT	Options to Purchase Common Stock	Award	$0	+350,000		$0.000000	350,000	03 Jul 2025	Common	350,000	$2.83	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Effective July 3, 2025, the reporting person was granted stock options to purchase an aggregate of 350,000 shares vesting 50% on the effective date, 25% on September 30,2025 and 25% on December 31,2025. The grant was a signing bonus for the reporting person entering into an employment agreement with the issuer. The exercise price is $2.83 per share.